Nirsevimab for Respiratory Syncytial Virus Prophylaxis in Newborns and Infants

• 2025

  Log in to bookmark this resource.

  Log in
• Bernhard Resch
PMID: 39998304DOI: https://doi.org/10.1056/evide2400440

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This editorial discusses the burden of respiratory syncytial virus (RSV) infection in young children, particularly infants under 6 months old or in their first RSV season. RSV can lead to severe lower respiratory tract infections, with 1 to 2% of at-risk newborns and infants requiring hospitalization for RSV bronchiolitis or pneumonia during the RSV season. Nirsevimab, a medication aimed at preventing RSV in newborns and infants, offers promise in reducing the impact of this virus.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Response

Bundles: Nirsevimab Library

Keywords: Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses

Institutions: Med Uni Graz

---

More like this

Readiness for and Response to Coronavirus Disease 2019 Among Pediatric Healthcare Providers: The Role of Simulation for Pandemics and Other Disasters 2021 · Medical University of Vienna, University of Tübingen, University of Bern, Medical University of Graz Healthcare Providers' and Pregnant People's Preferences for a Preventive to Protect Infants from Serious Illness Due to Respiratory Syncytial Virus 2024 · Oracle Life Sciences, Pfizer Inc. "Med-X": A Medical Examiner Surveillance Model for Bioterrorism and Infectious Disease Mortality 2007 · University of New Mexico

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---